Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation

European Journal of Clinical Pharmacology

Volumn 72, Issue 6, 2016, Pages 671-679

  Al Aieshy, Fadiea ^a   Malmström, Rickard E ^a   Antovic, Jovan ^a   Pohanka, Anton ^a   Rönquist Nii, Yuko ^a   Berndtsson, Maria ^a   Al Khalili, Faris ^b   Skeppholm, Mika ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

Author keywords

Anti FXa assay; LC MS MS; NOAC; POC assay; Rivaroxaban; Therapeutic drug monitoring

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; RIVAROXABAN;

AGED; ATRIAL FIBRILLATION; BLOOD; CLINICAL TRIAL; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIQUID CHROMATOGRAPHY; MALE; METABOLISM; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; TANDEM MASS SPECTROMETRY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CHROMATOGRAPHY, LIQUID; FACTOR XA; FACTOR XA INHIBITORS; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RIVAROXABAN; TANDEM MASS SPECTROMETRY;

EID: 84962892094     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-016-2060-y     Document Type: Article

References (27)

1. Patel MR, Mahaffey KW, Garg J, et al. (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891. doi:10.1056/NEJMoa1009638
2. Antovic JP, Skeppholm M, Eintrei J, et al. (2013) Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol 69(11):1875–1881. doi:10.1007/s00228-013-1550-4
3. Skeppholm M, Al-Aieshy F, Berndtsson M, et al. (2015) Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation. Thromb Res 136(1):148–153. doi:10.1016/j.thromres.2015.04.030
4. Reilly PA, Lehr T, Haertter S, et al. (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 63(4):321–328. doi:10.1016/j.jacc.2013.07.104
5. Camm AJ, Lip GY, De Caterina R, et al. (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33(21):2719–2747. doi:10.1093/eurheartj/ehs253
6. Heidbuchel H, Verhamme P, Alings M, et al. (2015) Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. doi:10.1093/europace/euv309
7. European Medicines Agency. Summary of product characteristics, Xarelto (rivaroxaban). Bayer Pharma AG. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. Accessed september 28 2015
8. Cuker A, Siegal DM, Crowther MA, et al. (2014) Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 64(11):1128–1139. doi:10.1016/j.jacc.2014.05.065
9. Samama MM, Contant G, Spiro TE, et al. (2013) Laboratory assessment of rivaroxaban: a review. Thromb J 11(1):11. doi:10.1186/1477-9560-11-11
10. Perzborn E, Strassburger J, Wilmen A, et al. (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939–an oral, direct Factor Xa inhibitor. J Thromb Haemost 3(3):514–521. doi:10.1111/j.1538-7836.2005.01166.x
11. Freyburger G, Macouillard G, Khennoufa K, et al. (2015) Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects? Blood Coagul Fibrinolysis. doi:10.1097/MBC.0000000000000371
12. Douxfils J, Tamigniau A, Chatelain B, et al. (2013) Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 110(4):723–731. doi:10.1160/TH13-04-0274
13. Samama MM, Martinoli JL, LeFlem L, et al. (2010) Assessment of laboratory assays to measure rivaroxaban–an oral, direct factor Xa inhibitor. Thromb Haemost 103(4):815–825. doi:10.1160/TH09-03-0176
14. European Medicines Agency. Guideline on bioanalytical method validation EMEA/CHMP/EWP/192217/2009, Committee for Medicinal Products for Human Use (CHMP). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf. Accessed October 5, 2015
15. Francart SJ, Hawes EM, Deal AM, et al. (2014) Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost 111(6):1133–1140. doi:10.1160/TH13-10-0871
16. Ebner M, Peter A, Spencer C, et al. (2015) Point-of-care testing of coagulation in patients treated with non-vitamin K antagonist oral anticoagulants. Stroke 46(10):2741–2747. doi:10.1161/STROKEAHA.115.010148
17. Mueck W, Borris LC, Dahl OE, et al. (2008) Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 100(3):453–461
18. Mueck W, Lensing AW, Agnelli G, et al. (2011) Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 50(10):675–686. doi:10.2165/11595320-000000000-00000
19. FDA. Center for drug evaluation and research, application number 022406Orig1s000. Clinical pharmacology and biopharmaceutics review (s) http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022406Orig1s000ClinPharmR.pdf. Accessed October 5 2015
20. Bardy G, Fischer F, Appert A, et al. (2015) Is anti-factor Xa chromogenic assay for Rivaroxaban appropriate in clinical practice? Advantages and comparative drawbacks. Thromb Res 136(2):396–401. doi:10.1016/j.thromres.2015.05.015
21. Konigsbrugge O, Quehenberger P, Belik S, et al. (2015) Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban. Ann Hematol 94(9):1463–1471. doi:10.1007/s00277-015-2407-y
22. Mani H, Herth N, Kasper A, et al. (2014) Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant. Ther Drug Monit 36(5):624–631. doi:10.1097/FTD.0000000000000064
23. Hillarp A, Baghaei F, Fagerberg Blixter I, et al. (2011) Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 9(1):133–139. doi:10.1111/j.1538-7836.2010.04098.x
24. Heidbuchel H, Verhamme P, Alings M, et al. (2013) European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15(5):625–651. doi:10.1093/europace/eut083
25. Summary of product characteristics, Lasix Retard (furosemide). Sanofi. http://www.fass.se/LIF/product?35&userType=0&nplId=19820429000034&docType=6. Accessed November 1 2015
26. Summary of product characteristics, Aldactone (spironolactone). Pfizer. http://www.fass.se/LIF/product?42&userType=0&nplId=19800613000071&docType=6. Accessed November 1 2015
27. FDA. Prescribing information. Reference ID: 3039818. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202439s000lbl.pdf. Accessed October 22 2015